Technical Analysis
Comprehensive insights into market trends, chart patterns, and key indicators. Equip yourself with the tools and strategies to make data-driven trading decisions.
Arm China appoints chip veteran Chen Feng as new CEO following leadership uncertainty. This strategic move aims to solidify leadership amidst US-China tech rivalry and intense competition in the global semiconductor market.
Arm China Appoints New CEO Amidst Global Tech Rivalry Read More »
Chile’s central bank is expected to hold its benchmark interest rate at 5.0% next week amid signs of moderating inflation. Market operators foresee the rate easing to 4.75% in 12 months, contingent on inflation nearing the target range.
Central Bank of Chile Expected to Hold Rates Steady Read More »
Graco’s Q4 earnings are expected tomorrow, with analysts predicting a 1.7% revenue decline to $556.9 million and EPS of $0.76. Will Graco beat expectations despite recent underperformance and sector headwinds?
Graco Q4 Earnings Preview: Anticipating a Revenue Decline Read More »
China directs state funds to boost its struggling stock market, hoping to restore confidence and stimulate demand. However, skepticism remains due to economic headwinds like deflation and geopolitical tensions.
China’s State-Driven Stock Market Revival: A Strategy Facing Skepticism Read More »
Explore Cathie Wood’s $1.5 million Bitcoin prediction by 2030 and the underlying thesis of institutional adoption and regulatory developments. This deep dive offers insights for long-term investors considering this digital asset.
Cathie Wood’s Bitcoin Price Prediction: A Deep Dive into the $1.5 Million Forecast Read More »
Avita Medical (RCEL) receives a Buy rating and $25 price target from Boral Capital, citing Recell’s potential in treating various skin conditions like burns and wounds. Boral anticipates substantial growth as Recell expands into trauma, surgical, and chronic wound care markets.
Avita Medical: Poised for Growth, Boral Capital Initiates Coverage with Buy Rating Read More »
Vertex Pharmaceuticals stock fell after mixed Phase 2 trial results for its lumbosacral radiculopathy drug, suzetrigine. While the drug reduced pain, the placebo group showed similar improvement, raising questions about its efficacy.
Vertex Pharmaceuticals Stock Falls After Mixed Phase 2 Trial Results Read More »
Ford beat Q4 earnings and full-year profit forecasts, but 2025 guidance is muted due to potential tariff impacts and market factors. The automaker projects a “roughly breakeven” Q1 2025 and lower full-year EBIT, sparking investor concern and a stock price drop.
Ford Posts Q4 Earnings Beat But Issues Muted 2025 Guidance Amidst Tariff Concerns Read More »
DOGE’s access to Treasury systems sparks fears of financial instability and data breaches, drawing criticism from experts and former Treasury secretaries. Aggressive cost-cutting measures, including access to sensitive payment data, raise concerns about national security and a potential U.S. default.
DOGE’s Treasury Access Sparks Financial and Security Concerns Read More »
Barclays exceeded 2024 profit expectations with a 24% surge, driven by strong investment banking and UK lending. The bank raised its 2025 RoTE target to ~11%, signaling confidence despite a complex UK economic landscape.
Barclays Exceeds Profit Expectations, Raises 2025 Targets Read More »
